# ANAVEX2-73 Study in Parkinson's Disease Dementia

> **NCT03774459** · PHASE2 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 132 (actual)

## Conditions studied

- Parkinsons Disease With Dementia

## Interventions

- **DRUG:** High dose ANAVEX2-73
- **DRUG:** Mid dose ANAVEX2-73
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03774459
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774459, "ANAVEX2-73 Study in Parkinson's Disease Dementia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03774459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*